DK200001171A - Farmaceutiske sammensætninger - Google Patents

Farmaceutiske sammensætninger Download PDF

Info

Publication number
DK200001171A
DK200001171A DK200001171A DKPA200001171A DK200001171A DK 200001171 A DK200001171 A DK 200001171A DK 200001171 A DK200001171 A DK 200001171A DK PA200001171 A DKPA200001171 A DK PA200001171A DK 200001171 A DK200001171 A DK 200001171A
Authority
DK
Denmark
Prior art keywords
pharmaceutical composition
inorganic salt
pharmaceutical compositions
cation
multivalent
Prior art date
Application number
DK200001171A
Other languages
English (en)
Inventor
Joseph Richard Creekmore
Norman Alfred Wiggins
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9884259&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK200001171(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of DK200001171A publication Critical patent/DK200001171A/da
Application granted granted Critical
Publication of DK178242B1 publication Critical patent/DK178242B1/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Description

PATENTKRAY 1. Farmaceutisk sammensætning omfattende (E)-7-[4-(4-fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R, 5S)-3,5-dihydroxyhept-6-ensyre eller et farmaceutisk acceptabelt salt deraf som den aktive bestanddel og et uorganisk salt, hvori kationen er multivalent. 2. Farmaceutisk sammensætning ifølge krav 1, hvori kationen af det uorganiske salt er valgt blandt calcium, magnesium, zink, aluminium og jem. 3. Farmaceutisk sammensætning ifølge krav 1, hvori det uorganiske salt er valgt blandt aluminiummagnesiummetasilicat, tribasisk calciumphosphat, tribasisk magnesiumphos-phat og tribasisk aluminiumphosphat. 4. Farmaceutisk sammensætning ifølge krav 3, hvori det uorganiske salt er aluminiummagnesiummetasilicat. 5. Farmaceutisk sammensætning ifølge ethvert af kravene 1-4, som er en tablet eller et pulver. 6. Farmaceutisk sammensætning ifølge ethvert af kravene 1-5, hvori der er mere end 5 mg aktiv bestanddel til stede. 7. Farmaceutisk sammensætning ifølge ethvert af kravene 1- 6, hvori der er mere end 10 mg aktiv bestanddel til stede. 8. Farmaceutisk sammensætning ifølge ethvert af kravene 1-7, hvori det uorganiske salt, hvori kationen er multivalent, ikke er syntetisk hydrotalcit. 9. Farmaceutisk sammensætning ifølge ethvert af kravene 1 -8, hvori forholdet mellem uorganisk salt og aktiv bestanddel er i området fra 1:80 til 50:1 på vægtbasis. 10. Farmaceutisk sammensætning ifølge ethvert af de foregående krav, som yderligere omfatter et eller flere fyldstoffer, bindemidler, desintegreringsmidler eller smøremidler. 11. Farmaceutisk sammensætning ifølge ethvert af kravene 1-6, hvori den aktive bestanddel er til stede i en mængde på 1 til 50 vægt% af sammensætningen. 12. Farmaceutisk sammensætning ifølge ethvert af kravene 1-6, hvori det uorganiske salt er til stede i en mængde på 1 til 50 vægt% af sammensætningen. 13. Farmaceutisk sammensætning ifølge krav 10, hvori fyldstoffet er til stede i en mængde fra 30 til 90 vægt% af sammensætningen. 14. Farmaceutisk sammensætning ifølge krav 10 eller 13, hvori bindemidlet er til stede i en mængde fra 2 til 90 vægt% af sammensætningen. 15. Farmaceutisk sammensætning ifølge krav 10,13 eller 14, hvori desintegrermgsmid-let er til stedet i en mængde fra 2 til 10 vægt% af sammensætningen. 16. Farmaceutisk sammensætning ifølge krav 10,13,14 eller 15, hvori smøremidlet er til stede i en mængde fra 0,5 til 3 vægt%. 17. Farmaceutisk sammensætning ifølge ethvert af de foregående krav, hvori den aktive bestanddel er calcramsaltet af (E)-7-[4-(4-fluorphenyl)-6-isopropyl-2-[methyl(methyl-sulfonyl)amino]pyrimidin-5-yl]-(3R, 5S)-3,5-dihydroxyhept-6-ensyre. 18. Anvendelse af et uorganisk salt, hvori kationen er multivalent, til stabilisering af forbindelsen (E)-7-[4-(4-fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyri- midin-5-yl]-(3R, 5S)-3,5-dihydroxyhept-6-ensyre eller et farmaceutisk acceptabelt salt deraf. 19. Anvendelse ifølge krav 18, hvori det uorganiske salt, hvori kationen er multivalent, er valgt blandt aluminiummagnesiummetasilicat, tribasisk calciumphosphat, tribasisk magnesiumphosphat og tribasisk aluminiumphosphat. 20. Anvendelse ifølge krav 19, hvori det uorganiske salt, hvori kationen er multivalent, er aluminiummagnesiummetasilicat. 21. Fremgangsmåde til fremstilling af en stabiliseret farmaceutisk sammensætning, som omfatter inkorporering af et uorganisk salt, hvori kationen er multivalent, i en farmaceutisk sammensætning indeholdende forbindelsen (E)-7-[4-(4-fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R, 5S)-3,5-dihydroxyhept-6-ensyre eller et farmaceutisk acceptabelt salt deraf. 22. Fremgangsmåde ifølge krav 21, hvori det uorganiske salt, hvori kationen er multivalent, er aluminiummagnesiummetasilicat.
DK200001171A 2000-01-26 2000-08-04 Farmaceutiske sammensætninger DK178242B1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0001621.2A GB0001621D0 (en) 2000-01-26 2000-01-26 Pharmaceutical compositions
GB0001621 2000-01-26

Publications (2)

Publication Number Publication Date
DK200001171A true DK200001171A (da) 2001-07-27
DK178242B1 DK178242B1 (da) 2015-09-28

Family

ID=9884259

Family Applications (3)

Application Number Title Priority Date Filing Date
DK200001170A DK200001170A (da) 2000-01-26 2000-08-04 Farmaceutiske sammensætninger
DK200001171A DK178242B1 (da) 2000-01-26 2000-08-04 Farmaceutiske sammensætninger
DK00953283T DK1223918T3 (da) 2000-01-26 2000-08-04 Farmaceutiske præparater omfattende en HMG-CoA-reductaseinhibitor

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK200001170A DK200001170A (da) 2000-01-26 2000-08-04 Farmaceutiske sammensætninger

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK00953283T DK1223918T3 (da) 2000-01-26 2000-08-04 Farmaceutiske præparater omfattende en HMG-CoA-reductaseinhibitor

Country Status (48)

Country Link
US (2) US6548513B1 (da)
EP (6) EP1251831A1 (da)
JP (3) JP4800467B2 (da)
KR (3) KR100388713B1 (da)
CN (3) CN101028268A (da)
AP (2) AP1449A (da)
AR (3) AR025055A1 (da)
AT (3) ATE232088T1 (da)
AU (5) AU781269C (da)
BE (2) BE1013413A3 (da)
BG (4) BG65234B1 (da)
BR (2) BR0003365A (da)
CA (3) CA2315141C (da)
CH (2) CH700184B1 (da)
CL (1) CL2007001807A1 (da)
CR (3) CR6568A (da)
CZ (3) CZ299105B6 (da)
DE (3) DE10038108A1 (da)
DK (3) DK200001170A (da)
EE (3) EE04990B1 (da)
ES (2) ES2155043B1 (da)
FI (3) FI121365B (da)
FR (2) FR2795324B1 (da)
GB (3) GB0001621D0 (da)
HK (4) HK1047052A1 (da)
HR (3) HRP20080525A2 (da)
HU (2) HUP0003111A3 (da)
IL (4) IL147870A (da)
IS (3) IS1940B (da)
IT (2) ITTO20000780A1 (da)
ME (4) MEP33708A (da)
MY (2) MY123650A (da)
NL (2) NL1015858C2 (da)
NO (4) NO327675B1 (da)
NZ (2) NZ519774A (da)
PL (2) PL196808B1 (da)
PT (3) PT102503B (da)
RS (1) RS50201B (da)
RU (2) RU2206324C1 (da)
SE (2) SE523471C2 (da)
SI (1) SI1223918T1 (da)
SK (2) SK283872B6 (da)
TR (3) TR200200270T2 (da)
TW (2) TW553749B (da)
UA (2) UA51853C2 (da)
WO (2) WO2001054668A1 (da)
YU (1) YU52902A (da)
ZA (2) ZA200003998B (da)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) * 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
EP1274401B2 (en) † 2000-04-10 2014-08-13 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
USRE44578E1 (en) 2000-04-10 2013-11-05 Teva Pharmaceutical Industries, Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
NZ535261A (en) * 2000-08-08 2004-12-24 Smithkline Beecham P A tablet comprising the hydrochloride salt of N-(1-nbutyl-4-piperidinyl)methyl]-3,4-[1,3]oxazino[3,2-a] indole-10-carboxamide
US6777552B2 (en) * 2001-08-16 2004-08-17 Teva Pharmaceutical Industries, Ltd. Processes for preparing calcium salt forms of statins
GB0028429D0 (en) * 2000-11-22 2001-01-10 Astrazeneca Ab Therapy
EP1911462A3 (en) * 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
US20050175687A1 (en) * 2001-01-30 2005-08-11 Mcallister Stephen M. Pharmaceutical formulations
GB0102342D0 (en) * 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
US7842308B2 (en) * 2001-01-30 2010-11-30 Smithkline Beecham Limited Pharmaceutical formulation
US7883721B2 (en) * 2001-01-30 2011-02-08 Smithkline Beecham Limited Pharmaceutical formulation
WO2004016262A1 (ja) * 2002-08-12 2004-02-26 Kyowa Hakko Kogyo Co., Ltd. アミノ酸含有チュアブル錠
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
US20080293750A1 (en) * 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
US20060019269A1 (en) * 2002-10-17 2006-01-26 Decode Genetics, Inc. Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
SI21402A (sl) 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
TW200526274A (en) * 2003-07-21 2005-08-16 Smithkline Beecham Plc Pharmaceutical formulations
WO2005023778A2 (en) * 2003-08-28 2005-03-17 Teva Pharmaceutical Industries Ltd. Process for preparation of rosuvastatin calcium
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
ES2655435T3 (es) * 2003-09-12 2018-02-20 Amgen Inc. Formulación de disolución rápida de cinacalcet
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
EP1601658A1 (en) * 2003-11-24 2005-12-07 Teva Pharmaceutical Industries Limited Crystalline ammonium salts of rosuvastatin
US7244844B2 (en) * 2003-12-02 2007-07-17 Teva Pharmaceutical Industries Ltd. Reference standard for characterization of rosuvastatin
US20100216863A1 (en) * 2004-01-30 2010-08-26 Decode Genetics Ehf. Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
US8158362B2 (en) * 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
PE20060003A1 (es) * 2004-03-12 2006-03-01 Smithkline Beecham Plc Formulacion farmaceutica polimerica para moldear por inyeccion
AU2005240137B2 (en) * 2004-05-04 2010-04-15 Innophos, Inc. Directly compressible tricalcium phosphate
GB0411378D0 (en) * 2004-05-21 2004-06-23 Astrazeneca Ab Pharmaceutical compositions
CN1323665C (zh) * 2004-06-16 2007-07-04 鲁南制药集团股份有限公司 治疗高血脂症的组合物
WO2006017357A1 (en) * 2004-07-13 2006-02-16 Teva Pharmaceutical Industries Ltd. A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step
WO2006017692A2 (en) * 2004-08-06 2006-02-16 Transform Pharmaceuticals, Inc. Novel fenofibrate formulations and related methods of treatment
US20070037979A1 (en) * 2005-02-22 2007-02-15 Valerie Niddam-Hildesheim Preparation of rosuvastatin
US20070167625A1 (en) * 2005-02-22 2007-07-19 Anna Balanov Preparation of rosuvastatin
KR101020024B1 (ko) * 2005-02-22 2011-03-09 테바 파마슈티컬 인더스트리즈 리미티드 로수바스타틴 알킬에테르를 함유하지 않는 로수바스타틴 및이의 염 및 이의 제조 방법
RU2303980C2 (ru) * 2005-06-03 2007-08-10 ОАО "Щелковский витаминный завод" Лекарственная форма с антиагрегационным действием и способ ее изготовления
CA2617805A1 (en) * 2005-08-04 2007-02-15 Transform Pharmaceuticals, Inc. Novel formulations comprising fenofibrate and a statin, and related methods of treatment
WO2007022488A2 (en) * 2005-08-16 2007-02-22 Teva Pharmaceutical Industries Ltd. Crystalline rosuvastatin intermediate
PT1928409E (pt) 2005-09-12 2012-11-27 Actelion Pharmaceuticals Ltd Composição farmacêutica estável que compreende uma pirimidina-sulfamida
PT1944029E (pt) * 2005-10-31 2012-02-09 Nissan Chemical Ind Ltd Preparação farmacêutica com excelente fotoestabilidade
EP1968593B1 (en) * 2005-12-20 2017-08-23 LEK Pharmaceuticals d.d. Pharmaceutical composition comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl-(3r,5s)-3,5-dihydroxyhept-6-enoic acid
HU227696B1 (en) * 2006-04-13 2011-12-28 Egyt Gyogyszervegyeszeti Gyar Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it
US8455640B2 (en) * 2006-05-03 2013-06-04 Msn Laboratories Limited Process for statins and its pharmaceutically acceptable salts thereof
HU227610B1 (en) * 2006-09-18 2011-09-28 Richter Gedeon Nyrt Pharmaceutical compositions containing rosuvastatin potassium
US8404841B2 (en) * 2006-10-09 2013-03-26 Msn Laboratories Limited Process for the preparation of statins and their pharmaceutically acceptable salts thereof
WO2008124121A1 (en) * 2007-04-06 2008-10-16 Scidose, Llc Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
WO2008124122A1 (en) * 2007-04-09 2008-10-16 Scidose, Llc Combinations of statins and anti-obesity agent and glitazones
EP2131835A1 (en) * 2007-04-09 2009-12-16 Scidose, Llc Combinations of statins and anti-obesity agent
CN101336920B (zh) * 2007-07-05 2013-06-05 江苏正大天晴药业股份有限公司 一种稳定的药物组合物
AU2009208610A1 (en) * 2008-01-30 2009-08-06 Lupin Limited Modified release formulations of HMG CoA reductase inhibitors
WO2009112870A1 (en) * 2008-03-11 2009-09-17 Belupo-Lijekovi I Kozmetika D.D. Pharmaceutical composition comprising rosuvastatin calcium and magnesium carbonate hydroxide pentahydrate as a stabilizer
WO2009143776A1 (zh) 2008-05-27 2009-12-03 常州制药厂有限公司 瑞舒伐他汀钙盐的制备方法及其中间体
WO2009150228A2 (en) * 2008-06-13 2009-12-17 Glaxo Group Limited Pharmaceutical formulations
DK2306982T3 (da) * 2008-06-27 2015-04-20 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Farmaceutiske præparater af rosuvastatin calcium
EP2138165A1 (en) 2008-06-27 2009-12-30 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising a statin
PT2309992T (pt) * 2008-06-27 2018-01-22 Krka Tovarna Zdravil D D Novo Mesto Composição farmacêutica compreendendo uma estatina
PL386051A1 (pl) * 2008-09-09 2010-03-15 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Stabilna doustna kompozycja farmaceutyczna zawierająca farmaceutycznie dopuszczalną sól kwsu [(E)-7-[4-(4-fluorofenylo)-6-izopropylo-2-[metylo(metylosulfonylo)amino]pirymidyn-5-ylo] (3R,5S)-3,5-dihydroksyhept-6-enowego
HU230877B1 (hu) * 2008-09-30 2018-11-29 EGIS Gyógyszergyár NyR Stabil kombinációs gyógyszerkészítmény
MX344885B (es) * 2008-11-10 2017-01-10 Psicofarma S A De C V Proceso para la obtencion de una composicion de rosuvastatina calcica y producto obtenido.
US8487105B2 (en) 2009-01-19 2013-07-16 Msn Laboratories Limited Process for preparing pitavastatin, intermediates and pharmaceuctically acceptable salts thereof
TR200902077A2 (tr) 2009-03-17 2010-01-21 Sanovel İlaç San.Veti̇c.A.Ş. Stabil rosuvastatin kompozisyonları
US8470805B2 (en) * 2009-04-30 2013-06-25 Kaohsiung Medical University Processes for preparing piperazinium salts of KMUP and use thereof
TR200904341A2 (tr) 2009-06-03 2010-12-21 Bi̇lgi̇ç Mahmut Rosuvastatin kalsiyum içeren kararlı farmasötik bileşimler.
EA201270269A1 (ru) 2009-08-13 2012-09-28 Синтон Б.В. Фармацевтическая таблетка, содержащая розувастатин кальция
WO2011086584A2 (en) 2010-01-18 2011-07-21 Msn Laboratories Limited Improved process for the preparation of amide intermediates and their use thereof
CN101766578B (zh) * 2010-02-09 2011-06-08 鲁南贝特制药有限公司 一种含瑞舒伐他汀钙的片剂及其制备工艺
TR201009397A2 (tr) 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Rosuvastatin içeren farmasötik bileşimler.
EP2566465A2 (en) 2010-05-04 2013-03-13 Mahmut Bilgic Stable rosuvastatin formulations
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
TWI462739B (zh) 2010-11-02 2014-12-01 Univ Kaohsiung Medical Ｓｉｌｄｅｎａｆｉｌ－同族物四級銨哌嗪鹽類之製備及醫療用途
EP2698159A4 (en) * 2011-04-12 2014-11-05 Sawai Seiyaku Kk PITAVASTATE-CONTAINING PREPARATION AND METHOD OF MANUFACTURING THEREOF
CA2835364C (en) 2011-05-20 2018-10-02 Astrazeneca Uk Limited Pharmaceutical composition of rosuvastatin calcium
RU2508109C2 (ru) * 2011-05-27 2014-02-27 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая композиция для лечения нарушений липидного обмена
WO2013172297A1 (ja) * 2012-05-14 2013-11-21 塩野義製薬株式会社 ６，７－不飽和－７－カルバモイルモルヒナン誘導体含有製剤
AR091706A1 (es) * 2012-07-11 2015-02-25 Teva Pharma Formulaciones de laquinimod sin agentes alcalinizantes
WO2014142521A1 (ko) 2013-03-12 2014-09-18 주식회사 엘지생명과학 발사르탄 및 로수바스타틴 칼슘을 포함하는 복합 제제 및 이의 제조방법
RO129060B1 (ro) 2013-04-25 2014-11-28 Antibiotice S.A. Compoziţie farmaceutică stabilă cu rosuvastatină calcică amorfă
RU2547574C2 (ru) * 2013-07-09 2015-04-10 Общество с ограниченной ответственностью "Трейдсервис" Лекарственная форма гиполипидемического действия и способ ее изготовления
KR101597004B1 (ko) 2013-07-25 2016-02-23 씨제이헬스케어 주식회사 서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제
BR112017009521A2 (pt) 2014-11-11 2017-12-19 Shionogi & Co comprimido de múltiplas camadas que contém um fármaco instável à luz
JP2016169198A (ja) * 2015-03-13 2016-09-23 大原薬品工業株式会社 ロスバスタチンカルシウムを含有する錠剤
JP6095176B2 (ja) * 2015-04-24 2017-03-15 大原薬品工業株式会社 ロスバスタチンカルシウムの光安定性が向上したフィルムコーティング錠剤
HK1258050A1 (zh) 2015-10-23 2019-11-01 Lyndra Therapeutics, Inc. 用於治疗剂缓释的胃驻留系统及其使用方法
EP3386488B1 (en) 2015-12-08 2023-09-06 Lyndra Therapeutics, Inc. Geometric configurations for gastric residence systems
EP3243506A1 (en) 2016-05-09 2017-11-15 Adamed sp. z o.o. Pharmaceutical composition
AU2017268840B2 (en) 2016-05-27 2022-02-10 Nortiva Bio, Inc. Materials architecture for gastric residence systems
US11576866B2 (en) 2016-09-30 2023-02-14 Lyndra Therapeutics, Inc. Gastric residence systems for sustained delivery of adamantane-class drugs
CN107913257A (zh) * 2016-10-10 2018-04-17 北京阜康仁生物制药科技有限公司 一种包含瑞舒伐他汀钙的药物组合物及其制备方法
US10600502B2 (en) 2016-12-20 2020-03-24 Astrazeneca Uk Ltd. Systems and methods for dispensing a statin medication over the counter
US12023406B2 (en) 2017-06-09 2024-07-02 Lyndra Therapeutics, Inc. Gastric residence systems with release rate-modulating films
JP2018027987A (ja) * 2017-11-24 2018-02-22 共和薬品工業株式会社 医薬組成物
CN112274487A (zh) * 2019-07-25 2021-01-29 北京福元医药股份有限公司 一种瑞舒伐他汀钙药物制剂
CN110638743B (zh) * 2019-10-25 2023-03-28 乐普制药科技有限公司 一种含布立西坦的组合物
US20220008519A1 (en) 2020-07-09 2022-01-13 Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) Treatment of severe acute respiratory syndrome-related coronavirus infection with klotho
GB2622822A (en) 2022-09-28 2024-04-03 Novumgen Ltd A rapidly disintegrating tablet of rosuvastatin and its process of preparation

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2262229A (en) * 1939-06-24 1941-11-11 Interchem Corp Pigment and method of preparation
GB653026A (en) 1947-07-02 1951-05-09 Merck & Co Inc Vitamin preparations
US4743450A (en) 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
US4868185A (en) * 1987-12-10 1989-09-19 Warner-Lambert Company 6-[[Substituted)pyrimidinyl)ethyl]- and ethenyl]tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
US4929620A (en) * 1987-12-10 1990-05-29 Warner-Lambert Company 5-pyrimidinyl-3,5-dihydroxy-6-heptenoic acid compounds useful as inhibitors of cholesterol biosynthesis
NO890521L (no) 1988-02-25 1989-08-28 Bayer Ag Substituerte pyrimidiner.
US5030447A (en) * 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
EP0367895A1 (en) * 1988-10-06 1990-05-16 Sandoz Ag Pyrimidinyl-substituted hydroxyacids, lactones and esters and pharmaceutical compositions containing them
US5004651A (en) 1989-01-24 1991-04-02 Abbott Laboratories Stabilizing system for solid dosage forms
US5130298A (en) 1989-05-16 1992-07-14 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
ATE112491T1 (de) 1990-09-13 1994-10-15 Akzo Nobel Nv Stabilisierte feste chemische zusammensetzungen.
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
RU2098411C1 (ru) * 1991-08-02 1997-12-10 Иституто Лусо Фармако д Италия С.п.А. Производные пиримидина, способ их получения, фармацевтическая композиция на их основе
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
US5478832A (en) 1992-05-08 1995-12-26 The Green Cross Corporation Quinoline compounds
ES2133158T3 (es) 1993-01-19 1999-09-01 Warner Lambert Co Formulacion ci-981 oral, estable y proceso de preparacion del mismo.
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
WO1997023200A1 (en) * 1995-12-22 1997-07-03 Kowa Company, Ltd. Pharmaceutical composition stabilized with a basic agent
DE69713948D1 (de) * 1996-04-23 2002-08-22 Janssen Pharmaceutica Nv Rasch-freisetzende pH-unabhängige feste Dosisformen enthaltend Cisaprid
ES2242398T3 (es) 1998-06-05 2005-11-01 Warner-Lambert Company Llc Estabilizacion de composiciones que contienen inhibidores de la enzima de conversion de la angiotensina utilizando oxido de magnesio.
SI20109A (sl) 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
GB9900339D0 (en) 1999-01-09 1999-02-24 Zeneca Ltd Chemical compounds
US6150410A (en) 1999-02-04 2000-11-21 Abbott Laboratories pH independent extended release pharmaceutical formulation
GB0000710D0 (en) * 1999-02-06 2000-03-08 Zeneca Ltd Drug combination
AR022462A1 (es) * 1999-02-06 2002-09-04 Astrazeneca Uk Ltd Uso de un agente que disminuye el colesterol
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
AU3653301A (en) 2000-01-28 2001-08-07 Merck & Co., Inc. Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug

Also Published As

Publication number Publication date
JP2007182452A (ja) 2007-07-19
FR2804025B1 (fr) 2002-08-23
JP2001206847A (ja) 2001-07-31
AP2002002591A0 (en) 2002-09-30
CN100528161C (zh) 2009-08-19
FI20001749L (fi) 2001-07-27
CN1319396A (zh) 2001-10-31
BG66168B1 (bg) 2011-10-31
EE200900047A (et) 2011-04-15
EP2774609A1 (en) 2014-09-10
FI111806B (fi) 2003-09-30
CZ290167B6 (cs) 2002-06-12
CA2315141C (en) 2009-08-18
HK1040936B (zh) 2010-06-11
TWI228050B (en) 2005-02-21
BG66159B1 (bg) 2011-09-30
DE10038110B4 (de) 2006-06-29
HUP0003111A3 (en) 2003-03-28
CH691347A5 (de) 2001-07-13
PL196808B1 (pl) 2008-02-29
SK283872B6 (sk) 2004-03-02
DE10038108A1 (de) 2001-08-02
UA77156C2 (en) 2006-11-15
MEP33808A (hr) 2010-10-10
RU2206324C1 (ru) 2003-06-20
RU2002122752A (ru) 2004-03-10
UA51853C2 (uk) 2002-12-16
ZA200003997B (en) 2000-08-14
HUP0003110A3 (en) 2003-02-28
NZ531474A (en) 2007-04-27
AR025055A1 (es) 2002-11-06
HK1200368A1 (en) 2015-08-07
ITTO20000779A0 (it) 2000-08-04
SE0002827L (sv) 2001-07-27
ZA200003998B (en) 2000-08-14
BG106393A (en) 2002-07-31
PL341853A1 (en) 2001-01-29
JP4800467B2 (ja) 2011-10-26
EP1223918B1 (en) 2003-02-05
ES2155043A1 (es) 2001-04-16
HRP20020097A2 (en) 2002-06-30
CL2007001807A1 (es) 2008-01-18
HK1036935A1 (en) 2002-01-25
CZ298411B6 (cs) 2007-09-26
AU2005202392A1 (en) 2005-06-30
CZ20002883A3 (cs) 2000-10-11
ITTO20000779A1 (it) 2002-02-04
IL150513A (en) 2012-12-31
KR100388713B1 (ko) 2003-06-25
HK1048950A1 (zh) 2003-04-25
IS6480A (is) 2002-07-23
RU2264210C2 (ru) 2005-11-20
MEP33708A (hr) 2010-10-10
SK11782000A3 (sk) 2001-12-03
FI20001750A0 (fi) 2000-08-04
HUP0003111A2 (hu) 2002-02-28
FI121365B (fi) 2010-10-29
IL147870A (en) 2003-10-31
PT1223918E (pt) 2003-06-30
SE0002826L (sv) 2001-07-27
ME00191B (me) 2010-10-10
SE0002827D0 (sv) 2000-08-04
ATE232088T1 (de) 2003-02-15
NO20003967L (no) 2001-07-27
HUP0003110A2 (hu) 2001-05-28
NO20071303L (no) 2001-07-27
BG110353A (en) 2009-09-30
AP1879A (en) 2008-08-14
AU781269B2 (en) 2005-05-12
GB2358583B (en) 2002-02-06
CZ299105B6 (cs) 2008-04-23
HK1040936A1 (zh) 2002-06-28
DK200001170A (da) 2001-01-27
HRP20020632A2 (en) 2004-12-31
PT102503B (pt) 2004-02-27
AU2005202392B2 (en) 2008-11-20
CR6687A (es) 2005-07-18
AR023624A1 (es) 2002-09-04
CN101028268A (zh) 2007-09-05
BR0003364A (pt) 2001-09-18
MY123650A (en) 2006-05-31
AU738074B2 (en) 2001-09-06
ES2171123A1 (es) 2002-08-16
NO20003968D0 (no) 2000-08-04
HU222578B1 (hu) 2003-08-28
NZ519774A (en) 2004-04-30
ME00202B (me) 2010-10-10
GB2358582A (en) 2001-08-01
CZ20002884A3 (cs) 2001-09-12
BR0003365A (pt) 2001-09-18
PT102504A (pt) 2001-07-31
EE05586B1 (et) 2012-10-15
DK1223918T3 (da) 2003-04-28
YU5202A (sh) 2004-12-31
HK1047052A1 (zh) 2003-02-07
JP4800988B2 (ja) 2011-10-26
KR20010077840A (ko) 2001-08-20
TR200200270T2 (tr) 2002-06-21
BG65234B1 (bg) 2007-09-28
JP2001206877A (ja) 2001-07-31
HRP20080525A2 (en) 2008-12-31
FI121589B (fi) 2011-01-31
GB2358583A (en) 2001-08-01
AU5184200A (en) 2001-08-02
US6548513B1 (en) 2003-04-15
TW553749B (en) 2003-09-21
ITTO20000780A1 (it) 2000-11-04
FR2795324A1 (fr) 2000-12-29
CR6568A (es) 2004-03-05
BE1013414A5 (fr) 2001-12-04
NO2010005I1 (no) 2010-05-03
SE523471C2 (sv) 2004-04-20
NO20003968L (no) 2001-07-27
AU2005202392C1 (en) 2016-06-02
IS6254A (is) 2002-01-29
SI1223918T1 (en) 2003-06-30
GB2358582B (en) 2004-09-29
CR10114A (es) 2008-08-21
HU0003111D0 (en) 2000-10-28
TR200701171T2 (tr) 2007-04-24
EP1251831A1 (en) 2002-10-30
EE200200411A (et) 2003-12-15
NO327554B1 (no) 2009-08-10
AT412062B (de) 2004-09-27
EE05221B1 (et) 2009-10-15
NO312434B1 (no) 2002-05-13
CA2639407A1 (en) 2001-07-26
CA2313783C (en) 2002-03-12
EP2018853A1 (en) 2009-01-28
PL341855A1 (en) 2001-07-30
AU6580000A (en) 2001-08-07
HU0003110D0 (en) 2000-10-28
DK178242B1 (da) 2015-09-28
KR100698333B1 (ko) 2007-03-23
SE523481C2 (sv) 2004-04-20
NO20003967D0 (no) 2000-08-04
IL187416A0 (en) 2008-02-09
HK1036934A1 (en) 2002-01-25
JP3267960B2 (ja) 2002-03-25
AP2002002409A0 (en) 2002-03-31
DE10038110A1 (de) 2001-08-23
EP1223918A1 (en) 2002-07-24
FI20001749A0 (fi) 2000-08-04
SK11792000A3 (sk) 2001-12-03
CA2315141A1 (en) 2001-07-26
CA2639407C (en) 2011-09-13
FI20105657L (fi) 2010-06-10
IL150513A0 (en) 2003-02-12
DE60001371T2 (de) 2004-01-22
ATA13612000A (de) 2004-02-15
ATA13602000A (de) 2004-02-15
NO327675B1 (no) 2009-09-07
BE1013413A3 (fr) 2001-12-04
MY122707A (en) 2006-04-29
PT102503A (pt) 2000-12-29
IS2805B (is) 2012-09-15
AT412063B (de) 2004-09-27
TR200201888T2 (tr) 2002-11-21
EP2133070A1 (en) 2009-12-16
KR20000072135A (ko) 2000-12-05
CH700184B1 (de) 2010-07-15
GB0019028D0 (en) 2000-09-27
IS8620A (is) 2007-03-07
US6316460B1 (en) 2001-11-13
WO2001054668A1 (en) 2001-08-02
AU2000264559A1 (en) 2001-08-07
AU781269C (en) 2006-11-30
NL1015859A1 (nl) 2001-07-27
FI20001750L (fi) 2001-07-27
ES2155043B1 (es) 2001-12-01
FR2795324B1 (fr) 2002-05-17
EE04990B1 (et) 2008-04-15
DE60001371D1 (de) 2003-03-13
AP1449A (en) 2005-07-28
AU5184100A (en) 2001-08-02
GB0001621D0 (en) 2000-03-15
CN1149997C (zh) 2004-05-19
YU52902A (sh) 2006-01-16
IS1940B (is) 2004-07-16
FR2804025A1 (fr) 2001-07-27
NL1015859C2 (nl) 2001-10-16
SE0002826D0 (sv) 2000-08-04
CA2313783A1 (en) 2000-10-16
RS50201B (sr) 2009-07-15
IL147870A0 (en) 2002-08-14
WO2001054669A1 (en) 2001-08-02
AR060248A2 (es) 2008-06-04
EP2266540A1 (en) 2010-12-29
BG106926A (bg) 2003-04-30
CN1282581A (zh) 2001-02-07
ES2171123B1 (es) 2003-11-16
GB0019029D0 (en) 2000-09-27
HRP20020097B1 (hr) 2010-12-31
HRP20020632B1 (en) 2010-12-31
KR20030036492A (ko) 2003-05-09
EE200200052A (et) 2003-04-15
NL1015858C2 (nl) 2001-07-27

Similar Documents

Publication Publication Date Title
DK200001171A (da) Farmaceutiske sammensætninger
JP2001206847A5 (da)
RU2002103603A (ru) Фармацевтические композиции, содержащие ингибитор hmg редуктазы
CA2356212A1 (en) Crystalline bis[(e)-7- [ 4-(4- fluorophenyl)- 6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin -5-yl] (3r,5s)-3, 5-dihydroxyhept -6-enoic acid]calcium salt
PT1263739E (pt) ''sais cristalinos do ácido 7-[4-(4-fluorofenil)-6-isopropil-2- [metil(metilsulfonil)amino]pirimidin-5-il]-(3r,5s)-3,5-di-hidroxihept- 6-enóico''
WO2010030201A3 (en) Stable oral pharmaceutical composition containing a pharmaceutically acceptable salt of [(e)-7-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidine-5-yl] (3r, 5s) - 3,5 dihydroxyhept-6- enoic acid
JP2009519985A5 (da)
WO2007071357A3 (en) Pharmaceutical composition comprising (e) -7- [4- (4-fluorophenyl) -6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin-5 -yl- (3r, 5s) -3, 5-dihydr0xyhept-6-en0ic acid
WO2009091346A2 (en) Stable pharmaceutical formulation and preparation methods

Legal Events

Date Code Title Description
PUP Patent expired

Expiry date: 20200804